How This Evidence Evolved
COPD Inhaler Strategy
From LAMA monotherapy through dual bronchodilation to eosinophil-guided triple therapy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Rate of all COPD exacerbations
Moderate/severe annual COPD exacerbations: indacaterol-glycopyrronium 0.84 vs glycopyrronium 0.95 (rate ratio 0.88, 95% CI 0.77-0.99, P=0.038)
Annual health-care-utilization exacerbation rate: salmeterol-fluticasone 1.28 vs tiotropium 1.32 (rate ratio 0.967, 95% CI 0.836-1.119, P=0.656)
Follow-up studies, subgroup analyses, and real-world validation
Annual rate of moderate or severe COPD exacerbations
Annual rate of moderate or severe exacerbations
All-cause mortality: FF/UMEC/VI vs UMEC/VI HR 0.72 (95% CI 0.53–0.99; p=0.042)
Integration into clinical practice guidelines and recommendations
Persistent exacerbations on LABA/LAMA: add ICS at eos ≥100 cells/µL. Consider withdrawal for pneumonia/major side effects; eos ≥300 raises withdrawal exacerbation risk.
Current standard of care and ongoing research directions
Annualized moderate/severe COPD exacerbations: dupilumab 0.78 vs placebo 1.10 (rate ratio 0.70; 95% CI 0.58–0.86; p<0.001).
Average FEV1 AUC 0–12 h difference vs placebo: ENHANCE-1 +87 mL (95% CI 55–119); ENHANCE-2 +94 mL (65–124); both p<0.001.
Landmark Trials in This Story
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
Rate of decline in FEV1
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
All-cause mortality
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Rate of all COPD exacerbations
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Moderate/severe annual COPD exacerbations: indacaterol-glycopyrronium 0.84 vs glycopyrronium 0.95 (rate ratio 0.88, 95% CI 0.77-0.99, P=0.038)
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
Annual health-care-utilization exacerbation rate: salmeterol-fluticasone 1.28 vs tiotropium 1.32 (rate ratio 0.967, 95% CI 0.836-1.119, P=0.656)
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Annual rate of moderate or severe COPD exacerbations
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Annual rate of moderate or severe exacerbations
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
All-cause mortality: FF/UMEC/VI vs UMEC/VI HR 0.72 (95% CI 0.53–0.99; p=0.042)
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Annualized moderate/severe COPD exacerbations: dupilumab 0.78 vs placebo 1.10 (rate ratio 0.70; 95% CI 0.58–0.86; p<0.001).
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Average FEV1 AUC 0–12 h difference vs placebo: ENHANCE-1 +87 mL (95% CI 55–119); ENHANCE-2 +94 mL (65–124); both p<0.001.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.